Recce Pharmaceuticals Ltd. announced it signed a Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a leading Indonesian biomedical organization, to accelerate the clinical development of Recce's anti-infective portfolio across Indonesia, with the aim of addressing the critical global health challenge of antimicrobial resistance (AMR). This is a historically significant bilateral initiative supported by the Australian and Indonesian governments. In a meeting together with Senior Executives from Recce and Etana, Her Excellency Penny Williams PSM, the Australian Ambassador to Indonesia, the Indonesian Minister of Health, Budi Sadikin, and the Head of the National Research and Innovation Agency (BRIN) were all in full support of this initiative.

Recce will collaborate with nationally selected biotech sponsor Etana to advance its clinical program with speed, accessibility, cost-effectiveness, including substantial government support, and quality. Coordinating bilateral efforts between the Australian and Indonesian governments and industry experts will provide Recce with market entry and penetration for international expansion opportunities. There is a significant need for new therapeutics in Indonesia, with the government increasing its focus on addressing infectious diseases and AMR. Specifically, more than 10% of Indonesia's adult population (19.5 million) have diabetes,2 a disease that can lead to higher probabilities of foot, urinary tract, and surgical site infections.3 Furthermore, a recent study showed that 15% of patients with sepsis in Indonesian hospitals had diabetes.